Are you a CIPA member?
Sign in to your account to register for the event
If you are not yet registered or a member of CIPA, please register here
Wednesday 7 August
The speaker will talk about his experience from working on three UPC cases, including working with the CMS, changing the language of the proceedings, and the court hearings themselves. As well as looking at these topics in their own right, he will compare & contrast them with how things work at the EPO.
All
Cameron focuses exclusively on the biotechnology and pharmaceutical fields, with an extensive EPO opposition practice (including many cases defending against multiple opponents) that runs alongside a large prosecution practice. These two areas often overlap, so strategic prosecution and parent/divisional strategies are a regular part of his workload. He is often engaged to advise clients at an early stage, in situations where future patent fights with competitors are inevitable.
Cameron acts for biotech companies including Guardant Health and Mammoth Biosciences, but most of his time is spent acting for blue-chip pharmaceutical companies, including Novartis, Merck, Gilead, and Lilly. This work includes defending patents covering blockbuster products which have attracted numerous EPO oppositions, whether from traditional generics companies or from biosimilars. He often acts as lead counsel at the EPO, but also collaborates with other firms to provide a second pair of eyes, and frequently plays a support role for national litigations. His expertise means that he has also been in demand as a UPC representative, acting for Novartis and Curio in two high profile UPC disputes.
No products in the cart.
Sign in to your account to register for the event
If you are not yet registered or a member of CIPA, please register here
The event has been added to your basket: